CHILDRENS HOSPITAL AND HEALTH SYSTEM INC
PO BOX 1997 MS 900, MILWAUKEE, WI 532011997 www.childrenswi.org

---

Organizations Filed Purposes: CHILDREN'S HOSPITAL AND HEALTH SYSTEM, INC. ("CHHS") IS COMMITTED TO ENSURING A HEALTHIER FUTURE FOR CHILDREN BY PROVIDING AN INTEGRATED AND COORDINATED HEALTH AND SOCIAL SERVICES NETWORK FOR INFANTS, CHILDREN AND ADOLESCENTS.

INTEGRATED AND COORDINATED HEALTH SERVICES NETWORK FOR INFANTS, CHILDREN AND ADOLESCENTS.

CHHS IS THE PARENT ORGANIZATION OF AN INTEGRATED SYSTEM OF ENTITIES PROVIDING COMPREHENSIVE MEDICAL CARE AND SOCIAL SERVICES TO CHILDREN FROM WISCONSIN AND THROUGHOUT THE COUNTRY. THE SYSTEM INCLUDES WISCONSIN'S ONLY FREESTANDING HOSPITAL DEDICATED SOLELY TO THE CARE AND TREATMENT OF CHILDREN, AS WELL AS VARIOUS OTHER FACILITIES PROVIDING INPATIENT AND OUTPATIENT CARE FOR CHILDREN WITH ALL TYPES OF ILLNESSES, INJURIES, BIRTH DEFECTS AND OTHER DISORDERS. THE SYSTEM ALSO INCLUDES EXTENSIVE RESEARCH, EDUCATION AND COMMUNITY OUTREACH PROGRAMS. ON AN AGGREGATE BASIS, THE ENTITIES WITHIN THE SYSTEM PROVIDED COMMUNITY BENEFITS OF NEARLY $131 MILLION.CHHS OVERSEES AND COORDINATES THE ACTIVITIES OF THE VARIOUS OPERATING ENTITIES WITHIN THE INTEGRATED SYSTEM, THROUGH THE PROVISION OF SUPPORTIVE AND ADMINISTRATIVE SERVICES ON A CONSOLIDATED, CENTRALIZED BASIS.

CHILDREN'S RESEARCH INSTITUTE ("CRI") IS A PROGRAM OF CHHS THAT ADVANCES PEDIATRIC MEDICAL RESEARCH IN WISCONSIN AND BEYOND. WITH A FOCUS ON TRANSLATIONAL RESEARCH, CRI IS TAKING DISCOVERIES FROM THE LABORATORY AND CONVERTING THEM TO NEW THERAPIES, DIAGNOSTICS, AND WAYS TO IMPROVE CARE AT PATIENTS' BEDSIDES. CHILDREN'S PROVIDES INSTITUTIONAL SUPPORT OF RESEARCH THROUGH INFRASTRUCTURE SUPPORT SUCH AS LABORATORY SPACE, SHARED EQUIPMENT, AND SHARED SERVICES (INCLUDING BIOSTATISTICIANS, GRANT WRITERS, AND CLINICAL RESEARCH NURSES) AS WELL AS PROGRAMMATIC SUPPORT FOR RESEARCHERS. A FEW EXAMPLES OF ONGOING RESEARCH PROJECTS ARE DESCRIBED BELOW.RESEARCHERS AT CRI ARE INVESTIGATING WAYS TO IMPROVE CARE FOR HEART TRANSPLANT PATIENTS, INCLUDING THE DEVELOPMENT OF A NEW METHOD TO MONITOR PEDIATRIC HEART TRANSPLANT RECIPIENTS AND IDENTIFY EARLY SIGNS OF TRANSPLANT REJECTION. TYPICALLY, HEART TRANSPLANT PATIENTS MUST UNDERGO A SERIES OF EIGHT TO TWELVE BIOPSIES PER YEAR TO MONITOR FOR TRANSPLANT REJECTION. THIS INVASIVE APPROACH POSES CERTAIN RISKS, AND CAN BE DIFFICULT FOR CHILDREN WHO HAVE ALREADY SPENT A CONSIDERABLE AMOUNT OF TIME HOSPITALIZED. THE RESEARCHERS HAVE DESIGNED A NONINVASIVE APPROACH THAT INVOLVES A SIMPLE BLOOD DRAW. THE LEVEL OF DONOR DNA IN THE BLOOD SERVES AS A BAROMETER OF HEART HEALTH; MORE THAN ONE-PERCENT OF DONOR DNA IN THE BLOOD INDICATES REJECTION. IN A PILOT STUDY, THIS METHOD SHOWED 100% SENSITIVITY.CRI FOCUSES EFFORTS ON CHILDHOOD CANCER RESEARCH, INCLUDING IMPROVING SURVIVORSHIP AND QUALITY OF LIFE FOR CHILDREN BATTLING SOME OF THE TOUGHEST FORMS OF THE DISEASE. ONGOING LABORATORY RESEARCH EFFORTS INCLUDE CANCER IMMUNOTHERAPY PROJECTS, WHERE OUR LABS ENGINEER NOVEL ANTIBODIES AND INCORPORATE THEM INTO ANTIBODY-BASED PRODUCTS FOR THERAPY SUCH AS BISPECIFIC ANTIBODIES AND CHIMERIC ANTIGEN RECEPTORS THAT FUNCTION TO REDIRECT POTENT IMMUNE EFFECTOR CELLS TOWARD ELIMINATION OF TUMOR CELLS. IN ADDITION, OUR RESEARCHERS ARE ACTIVE WITH THE THERAPEUTIC ADVANCES IN CHILDHOOD LEUKEMIA & LYMPHOMA (TACL) CONSORTIUM. THIS NATIONAL CONSORTIUM WAS ESTABLISHED TO DEVELOP AND CONDUCT PHASE I /II CLINICAL TRIALS OF NEW DRUGS AND NOVEL DRUG COMBINATIONS FOR RECURRENT CHILDHOOD LEUKEMIA OR LYMPHOMA. OUR RESEARCHERS ALSO CONTINUE TO PARTICIPATE IN THE COG (CHILDREN'S ONCOLOGY GROUP) CONSORTIUM FOR CLINICAL TRIALS OF NOVEL PEDIATRIC CANCER THERAPIES.RESEARCH IN IMPROVING NURSING CARE IS ALSO PART OF OUR RESEARCH PORTFOLIO, INCLUDING ONE PROJECT STUDYING WAYS TO ASSIST FAMILIES IN MANAGING COMPLEX CARE ISSUES AFTER THEY LEAVE THE HOSPITAL, POTENTIALLY IMPROVING ACCESS TO CARE AND POST DISCHARGE OUTCOMES FOR TRANSPLANT PATIENTS. THIS STUDY IS EVALUATING A NOVEL FAMILY CENTERED SELF-MANAGEMENT INTERVENTION THAT INCORPORATES AN INDIVIDUALIZED DAILY POST-DISCHARGE INTERACTIVE COMMUNICATION BETWEEN FAMILIES AND TRANSPLANT NURSES VIA MOBILE TECHNOLOGY. THE TOOL TRACKS DAILY FAMILY COPING, FAMILY SELF-MANAGEMENT BEHAVIORS OF COMPLEX CARE AT HOME, AND PARENT MANAGEMENT OF CHILDREN'S TRANSPLANT SYMPTOMS. THE TOOL MAY RESULT IN A PRE-IDENTIFIED TRIGGER AND ACTIVATE IMMEDIATE NOTIFICATION TO THE TRANSPLANT NURSE. THE ULTIMATE GOAL OF THE PROJECT IS TO IMPROVE ACCESS TO CARE.RESEARCHERS IN THE NEONATAL INTENSIVE CARE UNIT CONTINUE TO IMPROVE UNDERSTANDING OF PERSISTENT PULMONARY HYPERTENSION OF THE NEWBORN (PPHN), A LIFE-THREATENING CONDITION WHICH RESULTS FROM FAILURE OF PULMONARY VASCULAR RESISTANCE TO DECREASE AT BIRTH. IMPAIRED ANGIOGENESIS IN THE LUNG IS A KEY CONTRIBUTOR TO THE FAILED ADAPTATION. ENDOTHELIAL NITRIC OXIDE SYNTHASE (ENOS) PLAYS A CENTRAL ROLE IN THE REGULATION OF ANGIOGENESIS AND PULMONARY VASODILATION AT BIRTH. ONGOING STUDIES ARE INVESTIGATING THE CONTRIBUTION OF ENOS DYSFUNCTION TO IMPAIRED MITOCHONDRIAL BIOGENESIS AND EPIGENETIC ALTERATIONS IN ENOS GENE EXPRESSION IN PPHN, POTENTIALLY LEADING TO NOVEL THERAPY DEVELOPMENT TO RESTORE MITOCHONDRIAL BIOGENESIS AND ANGIOGENESIS IN INFANTS WITH PPHN.

CHHS PROVIDES VARIOUS OUTPATIENT HEALTH CARE SERVICES. IN 2019, THERE WERE 57,560 VISITS TO THE ORGANIZATION'S URGENT CARE CLINICS, AND 5,141 OUTPATIENT SURGICAL CASES PERFORMED AT THE ORGANIZATION'S AMBULATORY SURGICAL CENTER, THE SURGICENTER OF GREATER MILWAUKEE, LLC (A DISREGARDED ENTITY FOR FEDERAL TAX PURPOSES).

---

---

Data for this page was sourced from XML published by IRS (public 990 form dataset) from: https://s3.amazonaws.com/irs-form-990/202033189349306823_public.xml